Neuronetics Inc. (NASDAQ: STIM) announced that Chief Financial Officer Steven E. Pfanstiel will leave his position to pursue an opportunity outside the company. Pfanstiel will remain with the medical technology company through May 1, 2026, to support the transition.

The company stated that Pfanstiel's resignation is not the result of any dispute or disagreement with Neuronetics or its management regarding operations, policies, or practices. Neuronetics has initiated a search for his replacement.

The Malvern, Pennsylvania-based company develops products for patients with neurohealth disorders and manufactures the NeuroStar Advanced Therapy system. Neuronetics also operates Greenbrook TMS treatment centers across the United States.

In conjunction with the CFO departure announcement, Neuronetics reaffirmed the financial guidance it provided during its fourth quarter 2025 earnings call on March 17, 2026.

The information is based on a company press release statement.